SC Engineering "Cellontech's collagen intra-articular injection 'Katizol' making smooth landing in general hospitals"

[Asia Economy Reporter Hyunseok Yoo] Cellontech, a regenerative medicine specialized bio company affiliated with SCN Engineering, announced on the 25th that its intra-articular injection using collagen, ‘CartiZol (CartiZol, collagen-based tissue supplement)’, developed for the first time in Korea, has successfully landed in major general hospitals and tertiary hospitals.

A Cellontech official stated, “’CartiZol’ has landed in tertiary hospitals including Chonnam National University Hospital and Chungnam National University Hospital, as well as Pyeongtaek St. Mary’s Hospital, Jeju National University Hospital, Jeju Halla Hospital, and St. Carollo Hospital. Currently, the review and listing procedures for ‘CartiZol’ are underway at four tertiary hospitals in the Seoul and Gyeonggi areas, including university hospitals in Seoul, and the landing achievements in nationwide general hospitals and above are expected to continuously expand.”

Regarding this, the official added, “The function of ‘CartiZol’ through supplementation of the synovial membrane (synovium) met the medical field’s needs that require more than simple synovial fluid supplementation for degenerative arthritis treatment, and the approval by review committees of each general hospital is an objective recognition of ‘CartiZol’s effectiveness.”

Since its official release in June, ‘CartiZol’ has been supplied to numerous arthritis-specialized hospitals and clinics in Seoul and the metropolitan area within about two months.

‘CartiZol’, the first and only intra-articular injection using collagen in Korea that supplements defective or damaged articular cartilage by administering bio-collagen into the joint cavity, has obtained certification as a New Health Technology (NET) from the Ministry of Health and Welfare and recognition as a New Medical Technology (NECA).

A Cellontech official explained, “Due to the excellent efficacy of ‘CartiZol’ and the high satisfaction of medical staff and patients, supply requests are pouring in not only from individual clinics but also from general hospitals. The landing achievements of ‘CartiZol’ in general and tertiary hospitals symbolically confirm the favorable evaluation and trust of medical staff regarding the therapeutic usefulness and efficacy of ‘CartiZol’, which will further accelerate the enhancement of sales efficiency and the expansion of a solid distribution network.”

He continued, “Starting next month, when prescriptions at general and tertiary hospitals become full-scale, not only will ‘CartiZol’ sales increase, but the expansion of landing achievements at major hospitals nationwide, including tertiary hospitals currently under review, is expected to accelerate, leading to significant performance growth in the second half of the year.”

This content was produced with the assistance of AI translation services.